AM833, cagri · Evidence-based safety and harm-reduction overview.
| Also known as | AM833, cagri |
| Category | GLP-1 |
| trial_status | Investigational; not FDA-approved as of 2025 |
| mechanism_class | Amylin receptor agonist |
| route | Subcutaneous injection |
| dosing_frequency | Once weekly (in trials studied) |
| combination_partner | Often studied with semaglutide (GLP-1 agonist) |
| US legal status | Cagrilintide is investigational and not FDA-approved for any use; it is only legitimately available in authorized clinical trials, sometimes in combination with semaglutide (Rybelsus, Ozempic). Gray-market 'research' vials are unverified and illegal to sell for human consumption. |
Cagrilintide is an investigational long-acting synthetic amylin analog given by subcutaneous injection, typically once-weekly. It is studied for obesity and metabolic conditions, often in combination with a GLP-1 receptor agonist such as semaglutide, working through amylin signaling pathways that influence appetite, satiety, and metabolic rate.
Cagrilintide acts as an agonist at the amylin receptor, a G-protein-coupled receptor formed by the calcitonin receptor and a receptor-activity-modifying protein (RAMP). This signaling affects satiety centers in the brainstem and hypothalamus, slows gastric emptying, and modulates metabolic rate, complementing GLP-1 signaling when combined.
Cagrilintide (AM833) was developed by Novo Nordisk as an investigational amylin analog to complement GLP-1 agonists in combination weight-loss therapy. Clinical trials began in the early 2020s, with dual-therapy studies combining it with semaglutide generating interest in the obesity treatment community.
Research from clinical trials suggests cagrilintide can reduce body weight in trial participants, particularly when studied alongside semaglutide as a dual-therapy combination approach. Studies report effects on appetite suppression and satiety via amylin receptor (amylin-calcitonin) signaling pathways, but it remains investigational, long-term safety and outcome data are still accumulating in ongoing trials, and results from actual trial drug do not validate unregulated or mislabeled copies.
In clinical trials, cagrilintide was studied at escalating once-weekly subcutaneous doses; however, no definitive approved human dose has been established, and gray-market dosing is entirely speculative and unvalidated.
This is general research/context information, not medical advice or a recommended protocol.
Combining cagrilintide with semaglutide or other GLP-1 agents outside authorized clinical trials creates unstudied dual-agonist effects and significant risk; the combination requires medical supervision and dose escalation protocols.
If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.
Compare testing optionsNo. Cagrilintide is investigational and not FDA-approved for any indication. It is studied in clinical trials, often combined with semaglutide, but it is not available as an approved therapy outside research.
Cagrilintide is an amylin receptor agonist and acts through amylin signaling on appetite and satiety, whereas GLP-1 agonists like semaglutide act on the GLP-1 receptor. In trials they have been studied together as complementary and synergistic mechanisms.
Only within authorized clinical trials combining them. Self-sourcing both compounds and combining them outside trial supervision and medical monitoring is unsafe and unproven.
Cagrilintide is a synthetic amylin analog designed for improved stability and bioavailability, whereas amylin (pramlintide, Symlin) is an FDA-approved diabetes medication. They both act on amylin receptors but are distinct compounds.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.